1-氯-4-(1-(1-甲基乙基)环丙基)-苯 | 63340-07-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-氯-4-(1-(1-甲基乙基)环丙基)-苯
• 英文名称: Benzene, 1-chloro-4-(1-(1-methylethyl)cyclopropyl)-
• 英文别名: 1-chloro-4-(1-propan-2-ylcyclopropyl)benzene
• CAS: 63340-07-8
• 化学式: C₁₂H₁₅Cl
• 分子量: 194.7
• InChiKey: LLWMDTOIHHQUHQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

文献信息

• PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS
  申请人：Huang Taisheng

  公开号：US20110224190A1

  公开（公告）日：2011-09-15

  The present invention provides piperidin-4-yl azetidine derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase 1 (JAK1) and are useful in the treatment of diseases related to the activity of JAK1 including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.

  本发明提供了哌啶-4-基氮杂环丙烷衍生物，以及它们的组合物和使用方法，这些衍生物调节Janus激酶1（JAK1）的活性，并且在治疗与JAK1活性相关的疾病方面具有用处，例如炎症性疾病、自身免疫性疾病、癌症和其他疾病。
• SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS
  申请人：Das Jagabandhu

  公开号：US20130158001A1

  公开（公告）日：2013-06-20

  Disclosed are compounds of Formula (I): (I) or stereoisomers, salts, or prodrugs thereof, wherein: (i) R1 and R2 are independently C 1 -C 4 alkyl, or (ii) R 1 and R 2 together with the carbon atom to which they are attached, form a cyclic group; and Q is H, C 1-6 alkyl, phenyl or 5- to 6-membered heteroaryl substituted with zero to 3 substituents, and G is defined herein. Also disclosed are method of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. There compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and chronic inflammatory disease.

  本发明涉及式(I)的化合物：(I)或其立体异构体、盐或前药，其中：(i) R1和R2独立地是C1-C4烷基，或者(ii) R1和R2与它们连接的碳原子一起形成一个环状基团；Q为H、C1-6烷基、苯基或5-到6-成员杂环芳基取代零至3个取代基，G在此定义。还公开了使用这些化合物作为选择性G蛋白偶联受体S1P1激动剂的方法，以及包含这些化合物的制药组合物。这些化合物在治疗、预防或减缓多种治疗领域的疾病或疾病中是有用的，例如自身免疫性疾病和慢性炎症性疾病。
• NOVEL COMPOUNDS THAT ARE ERK INHIBITORS
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US20140296203A1

  公开（公告）日：2014-10-02

  Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1).

  本发明公开了式（1）的ERK抑制剂及其药学上可接受的盐。同时公开了使用式（1）的化合物治疗癌症的方法。
• OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS
  申请人：Butlin Roger John

  公开号：US20090215779A1

  公开（公告）日：2009-08-27

  Compounds of Formula (I): wherein R 1 -R 2 , W and Y are as described in the specification, and their salts and pro-drugs, are inhibitors of DGAT and are thereby useful in the treatment of, for example, obesity. Processes for preparing compounds of formula (I) are also described.

  式(I)的化合物：其中R1-R2、W和Y如规范所述，以及它们的盐和前药，是DGAT的抑制剂，因此在治疗肥胖症等方面是有用的。本文还描述了制备式(I)化合物的过程。
• US20140275031A1
  申请人：——

  公开号：US20140275031A1

  公开（公告）日：2014-09-18